Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

electroCore Announces Reverse Stock Split 14-02-2023, 22:39

Solutions to stop a global crisis: “Building Safe Futures: Solutions to End Childhood Sexual Violence” provides a roadmap to end childhood sexual violence 23-10-2024, 19:00